With advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets, often referred to as targeted covalent inhibitors (TCIs).  In this webinar, experts discuss innovative approaches to screen for covalent binders, strategies for the synthesis of covalent warheads, and assays to optimize the ADME/DMPK properties of these molecules. …Read More >

In this webinar, our experts discuss recent advancements in peptide drug discovery, including the evolution of mRNA display and peptide DNA-encoded library (DEL) technology for hit generation and selection, as well as novel cyclization techniques and their combinations for peptide conformational rigidity. This webinar offers a comprehensive perspective on strategies that are crucial for achieving …Read More >

In this webinar, experts present research strategies for the discovery of targeted protein degraders. Over the past decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. Since 2016, WuXi AppTec has built a comprehensive TPD discovery service platform, adept in over 20 …Read More >

High throughput experimentation (HTE) is frequently employed to identify reaction conditions for challenging transformations, giving access to a diverse array of medicinal chemistry targets. In parallel to using conventional batch reactions, we also incorporate flow chemistry into early phase synthesis to help with reaction selectivity and optimization, up-scaling, and solving specific chemical problems. In this …Read More >

A new wave of drugs that achieves targeted delivery of radioisotopes is rapidly gaining momentum.  As the discovery pipeline widens and new drug approvals increase, the field is expanding and becoming more diverse in the strategies employed to deliver cell-killing radioisotopes. One area that is showing considerable promise is the incorporation of an isotope-chelating moiety …Read More >

Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, has led to progress in the research and development of drugs for rare diseases. Despite these advances, many rare diseases still lack useful treatments and the need for new approaches remains high. In this webinar, we discuss important trends in …Read More >

Powerful biophysical and structural biology tools enable the study of large numbers of fragments and are opening new possibilities in the treatment of various diseases. In this webinar, WuXi AppTec presents the results of a conventional and covalent fragment-based drug discovery screen, and our expert speaker discusses how orthogonal biophysical and structural methods enable the …Read More >

Viral vectors, such as AAV, have emerged as one of the most commonly used gene delivery vehicles. In this webinar, our speakers discuss how WuXi AppTec can help teams engineer and optimize viral vectors, and how best to utilize a range of in vitro and in vivo assays in our services platform to support the …Read More >

In this webinar, our expert speakers showcase our automatic DNA-encoded library (DEL) screening device, DELman. DNA-encoded library technology has proven to be a powerful tool for drug discovery. There are now several DEL-derived candidates in clinical stage. DEL enables researchers to explore vast chemical space with millions to billions of compounds. With DELman and other …Read More >